In the USA, many common generic drugs beat brand names when it comes to safety, efficacy and cost. Yet many consumers are not taking advantage of the discount drug programs offering these drugs at prices as low as $4 a month, according to a new report from Consumer Reports, an American magazine published monthly by Consumers Union.
"Retailers like Kmart, Target, Walgreens and Walmart have been steadily expanding their discount programs, offering $4 a month prescriptions for drugs that our evidence based program deems 'best buys'," said Lisa Gill, editor of Consumer Reports Best Buy Drugs (BBD). "We suspect that consumers aren't taking full advantage of these programs because of the constant din of drug advertising which is steering consumers toward overpriced brand name drugs," she added.
Consumer Reports BBD identifies "best buys" based on a review of the medical evidence in partnership with the Drug Effectiveness Review Project (DERP), based at Oregon Health & Science University. For each class of drugs to treat a given condition, Consumer Reports BBD uses an analysis of hundreds of studies - and sometimes thousands - by DERP to derive its "best buy" designations. The reports, which cover 25 classes of drugs for more than 35 conditions, are available for free at www.ConsumerReportsHealth.org/BestBuyDrugs
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze